Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Therapie|November 18, 2023
Cutaneous adverse drug reactionsThomas Bettuzzi, Paola Sanchez-Pena, Bénédicte Lebrun-Vignes
Therapie|March 14, 2023
French pharmacovigilance survey of casirivimab - imdevimab monoclonal antibodies in coronavirus disease (COVID-19)Claire de Canecaude, François Montastruc, Sandrine Bergeron, et al.
Therapie|May 14, 2022
Comparative study of the adverse event profile of hydroxychloroquine before and during the Sars-CoV2 pandemicPauline Lory, Jeffrey Lombardi, Clémence Lacroix, et al.
Cardiovascular Drugs and Therapy|August 26, 2021
Neurocognitive Disorders Associated with PCSK9 Inhibitors: a Pharmacovigilance Disproportionality AnalysisAmandine Gouverneur, Paola Sanchez-Pena, Gwenaelle Veyrac, et al.
Therapie|July 11, 2020
Calcium channel blocker exposure and psoriasis risk: Pharmacovigilance investigation and literature dataBrahim Azzouz, Delphine Laugier-Castellan, Paola Sanchez-Pena, et al.
British Journal of Clinical Pharmacology|September 29, 2005
Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysisPaola Sanchez-Pena, Jean-Sébastien Hulot, Saïk Urien, et al.
Critical Care Medicine|February 27, 2009
Experience of diffusion tensor imaging and 1H spectroscopy for outcome prediction in severe traumatic brain injury: Preliminary resultsEléonore Tollard, Damien Galanaud, Vincent Perlbarg, et al.
British Journal of Clinical Pharmacology|August 26, 2022
Peripheral neuropathies after BRAF and/or MEK inhibitor treatment: A pharmacovigilance studyAlberto Picca, Cristina Birzu, Giulia Berzero, et al.
Intensive Care Medicine|September 18, 2009
A multiparameter panel method for outcome prediction following aneurysmal subarachnoid hemorrhageNatacha Turck, Laszlo Vutskits, Paola Sanchez-Pena, et al.
Pageof 2